ArticleFrontiers in pharmacology2025
The functional roles of deoxyelephantopin potential target circTNPO3 in regulating pancreatic cancer malignant phenotype and gemcitabine chemoresistance via miR-188-5p/CDCA3/TRAF2-mediated remodeling of NF-κB signaling pathway.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer (PC) has been one of the most severe digestive system malignant tumor with poor prognosis that threatens human health. Chemotherapy is essential for patients with advanced PC, but unfortunately the curative effect is limited by chemoresistance. CircTNPO3, a recently discovered circular RNA (circRNA), has been indicated to be associated with multi-types of tumors. However, the function and mechanism of circTNPO3 in regulating PC malignant phenotype and chemoresistance still remain obscure. Methods: qRT-PCR and ISH were used to analyze circTNPO3 expression in PC cells and pathological specimens. The subcellular localization of circTNPO3 was visualized through nucleoplasmic RNA separation and FISH assays. The effect of cicTNPO3 on PC cell proliferation, migration and invasion was assessed using EdU, colony formation, wound healing and Transwell assays respectively. Cell apoptosis was detected using ELISA, AO/EB, Hoechst 33342 and flow cytometry assays. The binding potential between circTNPO3, miR-188-5p and CDCA3 was verified by Ago2-RIP, RNA pull down and dual-luciferase reporter assays. The relationship between CDCA3, TRAF2 and NF-κB-p65 was analyzed using Pearson correlation, and the expression was detected using immunoblotting. The nucleus translocation of p65 was evaluated using IF assay. The effect of circTNPO3 on PC growth and metastasis was analyzed using subcutaneous and lung metastatic tumor models Results: CircTNPO3 was aberrantly highly expressed in PC cells and tissues, and negatively associated with patient prognosis and gemcitabine chemotherapy sensitivity. Functionally, silencing circTNPO3 attenuated the malignant phenotypes and chemoresistance of PC Conclusion: CircTNPO3 acted as an oncogenic and chemoresistant gene in PC, mechanically through targeting miR-188-5p and regulating CDCA3, TRAF2 and NF-κB signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.